

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

03/22/2002			
	Lou Franciscus M. H. De Leij	05032-00098	1723
10/29/2007 COFF LTD		EXAM	INER ,
28 STATE STREET 28th FLOOR BOSTON, MA 02109-9601		QIAN, CELINE X	
		ART UNIT	PAPER NUMBER
		1636	
	·	MAH DATE	DELIVERY MODE
			PAPER
	COFF, LTD. T	COFF, LTD.	OFF, LTD. QIAN, CE O9-9601 ART UNIT

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

•		Application No.	Applicant(s)	
5		10/009,579	DE LEIJ ET AL.	
	Office Action Summary	Examiner	Art Unit	
		Celine X. Qian Ph.D.	1636	
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the	ne correspondence address	
A SH WHIC - Exter after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. O period for reply is specified above, the maximum statutory period we are to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICAT 16(a). In no event, however, may a reply to 17 reply and will expire SIX (6) MONTHS 18 cause the application to become ABAND	FION. be timely filed from the mailing date of this communication. ONED (35 U.S.C. § 133).	
Status			•	
1)⊠	Responsive to communication(s) filed on 22 Au	<u>ıgust 2007</u> .	•	
2a) <u></u>	This action is FINAL . 2b)⊠ This action is non-final.			
3)	Since this application is in condition for allowar	nce except for formal matters,	prosecution as to the merits is	
	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11	, 453 O.G. 213.	
Dispositi	ion of Claims			
5)□ 6)⊠ 7)□	Claim(s) 1,2,4-9,20,21 and 24 is/are pending in 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) 1,2,4-9,20,21 and 24 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or	vn from consideration.		
	on Papers	•		
9) <u>□</u> 10)⊠	The specification is objected to by the Examiner The drawing(s) filed on 30 October 2001 is/are: Applicant may not request that any objection to the or Replacement drawing sheet(s) including the correction The oath or declaration is objected to by the Ex	a) \square accepted or b) \square object drawing(s) be held in abeyance. ion is required if the drawing(s) is	See 37 CFR 1.85(a). s objected to. See 37 CFR 1.121(d).	
Priority u	ınder 35 U.S.C. § 119			
12) <u>□</u> a)	Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau See the attached detailed Office action for a list of	s have been received. s have been received in Appli ity documents have been rec ı (PCT Rule 17.2(a)).	cation No eived in this National Stage	
		•		
Attachmen 1) Notice	t(s) ce of References Cited (PTO-892)	4) 🔲 Interview Sumn	nary (PTO-413)	
2) Notice 3) Information	the of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) er No(s)/Mail Date	Paper No(s)/Ma		

Application/Control Number: 10/009,579

Art Unit: 1636

DETAILED ACTION

Claims 1, 2, 4-9, 20, 21 and 24 are pending in the application.

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 8/22/07 has been entered.

Response to Amendment

The rejection of claim 14 under 35 U.S.C.112 1st paragraph is moot because the claim is canceled.

The rejection of claims 1, 2, 4-9, 20, 21 and 24 under 35 U.S.C.112 1st paragraph has been withdrawn in light of Applicant's amendment.

Claims 1, 2, 4-9, 20, 21 and 24 are rejected under 35 U.S.C.112 2nd paragraph for reasons set forth below.

A telephone call was made on 10/25/07 to discuss the case for a potential allowance but fail to Applicant's representative. The office action is thus issued.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Application/Control Number: 10/009,579

Art Unit: 1636

7

Claims 1, 2, 4-9, 20, 21 and 24 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Regarding claim 1, the recitation of "a promoter region encoding nucleotides 3200 to 3556 of SEQ ID NO:5" renders the claim indefinite because a promoter does not encodes nucleotides. Claims 2, 4-9, 20, 21 and 24 are rejected because they depend on claim 1. It would be remedial to amend the claim to recite "comprising."

Regarding claim 7, the recitation of "an isolated or recombinant nucleic acid sequence according to claim 1 further comprising a suicide gene or functional fragment thereof" renders the claim indefinite because it is unclear it the functional fragment is for the nucleic acid according to claim 1 or the suicide gene.

Claim Objections

Claims 2, 4-9, 20, 21 are objected to for reciting "an isolated or recombinant nucleic acid according to claim 1 or 5 or 20" because the parent claim is directed to only one isolated or recombinant nucleic acid. It would be remedial to change "a" to "the."

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celine X. Qian Ph.D. whose telephone number is 571-272-0777. The examiner can normally be reached on 9:30-6:00 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joe Woitach Ph.D. can be reached on 571-272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/009,579

Art Unit: 1636

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Celine X Qian Ph.D. Examiner Art Unit 1636

CELINE QIAN, PH.D. PRIMARY EXAMINER